Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 4.4% – Time to Buy?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s stock price was up 4.4% during trading on Thursday . The company traded as high as $23.80 and last traded at $24.09. Approximately 104,316 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 602,096 shares. The stock had previously closed at $23.08.

Analyst Ratings Changes

A number of research analysts recently commented on KNSA shares. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Trading Up 4.1 %

The company has a market capitalization of $1.75 billion, a PE ratio of -171.70 and a beta of 0.48. The stock’s 50-day moving average is $20.16 and its two-hundred day moving average is $22.08.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million during the quarter, compared to analysts’ expectations of $123.42 million. During the same period last year, the company earned $0.35 earnings per share. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year. On average, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Mark Ragosa sold 36,372 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $510,815.50. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,766 shares of company stock valued at $2,011,735 in the last ninety days. 54.57% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors have recently modified their holdings of KNSA. Quarry LP purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $50,000. Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $61,000. KLP Kapitalforvaltning AS purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $158,000. Bellevue Group AG purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $160,000. Finally, Tower Research Capital LLC TRC increased its holdings in Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after buying an additional 4,575 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.